Nurix Therapeutics Gains 50% PreMarket on $2.3B Roche Blood Cancer Deal
NRIX•Roche will pay Nurix $700M upfront and up to $1.6B in milestones under a $2.3B collaboration to develop bexobrutideg for chronic lymphocytic leukemia with costs split 60:40. Nurix Therapeutics shares surged about 50% premarket as bexobrutideg targets a potential $41 billion blood cancer market.
1. Deal Terms
Nurix and Roche entered an exclusive collaboration valued at up to $2.3 billion to develop and commercialize bexobrutideg, an investigational Bruton’s Tyrosine Kinase degrader for chronic lymphocytic leukemia. Nurix receives $700 million upfront and is eligible for up to $1.6 billion in milestone payments.
2. Financial Structure
Under the agreement, development costs will be shared 60:40, with Roche bearing the larger portion, while US profits will be split evenly. Roche holds commercialization rights outside the US in exchange for low- to high-teens sales royalties paid to Nurix.
3. Clinical Focus and Market Potential
Bexobrutideg aims to address recurring blood cancers with potential advantages in tolerability and efficacy over existing therapies. Analysts estimate the chronic lymphocytic leukemia market could reach $41 billion, positioning the therapy for significant commercial impact if approved.
4. Market Reaction
Nurix Therapeutics shares jumped approximately 50% in premarket trading after the deal announcement, making it one of the top gainers. The collaboration is expected to close in the third quarter of this year, pending customary regulatory and closing conditions.
